In its upcoming report, Abbott (ABT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting an increase of 5.3% compared to the same period last year. Revenues are forecasted to be $10.56 billion, representing a year-over-year increase of 4.1%.

The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

In light of this perspective, let's dive into the average estimates of certain Abbott metrics that are commonly tracked and forecasted by Wall Street analysts.

Analysts' assessment points toward 'Net sales- Medical Devices- Diabetes Care' reaching $1.72 billion. The estimate indicates a change of +16.6% from the prior-year quarter.

The average prediction of analysts places 'Net sales- Nutrition' at $2.17 billion. The estimate indicates a change of +4.7% from the prior-year quarter.

Analysts forecast 'Net sales- Diagnostics' to reach $2.31 billion. The estimate suggests a change of -5.9% year over year.

The consensus estimate for 'Net sales- Medical Devices- Neuromodulation- Total' stands at $243.18 million. The estimate indicates a year-over-year change of +7.1%.

The combined assessment of analysts suggests that 'Net sales- Diagnostics- U.S.' will likely reach $919.77 million. The estimate suggests a change of -9.2% year over year.

It is projected by analysts that the 'Net sales- Diagnostics- International' will reach $1.39 billion. The estimate points to a change of -3.4% from the year-ago quarter.

Analysts predict that the 'Net sales- Nutrition- International' will reach $1.25 billion. The estimate indicates a year-over-year change of +3.4%.

Analysts expect 'Net sales- Nutrition- U.S.' to come in at $918.13 million. The estimate indicates a change of +6.8% from the prior-year quarter.

According to the collective judgment of analysts, 'Net sales- Medical Devices- Neuromodulation- International' should come in at $44.88 million. The estimate suggests a change of +15.1% year over year.

The consensus among analysts is that 'Net sales- Medical Devices- Rhythm Management- U.S.' will reach $288.24 million. The estimate points to a change of +6.4% from the year-ago quarter.

Based on the collective assessment of analysts, 'Net sales- Medical Devices- Rhythm Management- International' should arrive at $305.66 million. The estimate indicates a change of +4.7% from the prior-year quarter.

The collective assessment of analysts points to an estimated 'Net sales- Medical Devices- Structural Heart- U.S.' of $259.72 million. The estimate points to a change of +16.5% from the year-ago quarter.

View all Key Company Metrics for Abbott here>>>

Over the past month, Abbott shares have recorded returns of -1% versus the Zacks S&P 500 composite's +5.4% change. Based on its Zacks Rank #3 (Hold), ABT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research